Apricus Biosciences (APRI) announced that it has expanded its exclusive distribution deal with Swiss firm Ferring Pharmaceuticals related to topical erectile dysfunction cream Vitaros. The new agreement adds 19 countries plus Hong Kong to Ferring's previous territory of Latin America and (recently) the United Kingdom. The existing marketing authorizations will be transferred to Ferring from Sandoz pursuant to the termination of Sandoz's license. According to the new agreement, Apricus is eligible to receive an additional $3.6M in upfront and pre-commercialization payments as well as up to an additional $1.5M in launch-related milestones. It can earn up to $34M in total milestones when the previous distribution agreement is included. Sales-based royalties will be high single-digit to low double-digit.